Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM) -- Ignore unavailable to you. Want to Upgrade?

To: xray who wrote (66)	6/22/1998 2:07:00 PM
From: John Fairchild	Read Replies (1) \| Respond to of 134

Immune Network Research Ltd - Primate research progress report Immune Network Research Ltd IMMShares issued 199704521998-06-19 close $0.2Monday Jun 22 1998VANCOUVER, B.C. (June 22, 1998) - Victor Jones, President, reports that the second phase primate study is proceeding as expected and with the encouraging condition of the macaques under study the Company has initiated steps for the production of additional monoclonal antibody 1F7 (mAb 1F7). The mAb 1F7 is required for a toxicity study in another animal species and may be used for a second injection of the current macaque group in an extension to the present study. Toxicity studies in primates and other animals are a prerequisite for approval of an Investigational New Drug (IND) trial using mAb 1F7 in humans. The Company, together with its scientific advisory board and researchers, is reviewing additional research programs which would build on its core monoclonal antibody and immune system technologies and expand the research programs on mAb 1F7. The second phase primate study is evaluating the proprietary mAb 1F7 for use as an adjuvant or therapeutic for human disease caused by the HIV and AIDS. Five SHIV89.6P-infected and two healthy macaques received a series of five injections of mAb 1F7 in April at the Oregon Regional Primate Centre and along with two control animals have been under close observation for changes in immune system response and viral load for seventy-six days. "Blood plasma and tissue sampling over the six month duration of the study will provide important data on virus neutralizing antibody levels, immune response, and viral load to determine whether mAb 1F7 promotes restoration of an already impaired immune system" reported Dr. Sybille Mller, Chief Scientist of Immpheron, Inc. in charge of the study. The Phase II primate study commenced after promising findings in an earlier study with macaques that showed mAb 1F7 appeared to increase the breadth and potency of virus neutralizing antibodies. Results of that study were published in the prestigious "Proceedings of the National Academy of Science USA" (PNAS Vol. 95 pp. 276-281, January 6, 1998). The Company has scheduled its 1998 Annual General Meeting for Monday, June 29, in Vancouver, BC. Victor J. E. Jones President THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE. Immune Network Research Ltd. 900 - 475 Howe Street Vancouver, B.C., Canada V6C 2B3 Tel. (604) 689-3923; Fax. (604) 684-5854 www.stockgroup.com/imm.html Trading Symbol: IMM.VSE (c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com